Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Documenti analoghi

• The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage
  di: Jean‐Matthieu L'Orphelin, et al.
  Pubblicazione: (2025)
• Real‐world outcomes of adjuvant therapies in stage III / IV melanoma: Insights from the French RIC ‐ MEL cohort
  di: M. Vuillemey, et al.
  Pubblicazione: (2025)
• Melanosis and isolated follicular vitiligo during checkpoint inhibitors for metastatic melanoma
  di: Valentine Salvestrini, et al.
  Pubblicazione: (2024)
• Inter‐ and intra‐observer agreement among dermatologists in assessing suspected melanoma lesions captured by general practitioners with smartphones
  di: Edmond Démoulins, et al.
  Pubblicazione: (2025)
• Comparison of an AI‐based prognostic assay with gene expression profiling in early‐stage melanoma
  di: Céline Bossard, et al.
  Pubblicazione: (2026)